Roth Capital Downgrades Tonix Pharma (TNXP) to Neutral Citing PTSD Setback
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/7/2026
- Nasdaq set to fall at open as DeepSeek's AI chip push rattles markets
- Oil gains after vessels attacked near Strait of Hormuz
- Citi says SpaceX stock has path to $900+ valuation. Here’s how
- Tesla stock target lifted at RBC on potential SpaceX merger
- Short squeezes more likely than widespread selling: Citi
- Rivian Automotive (RIVN) files for 75M share offering
- Rivian offers Q2 2026 revenue outlook, cash position grows
- Nokia OYJ (NOKIA:FH) (NOK) PT Raised to EUR14 at Kepler Cheuvreux
- Meta capex to surge in 2027, neocloud fears ’erroneous’ - SemiAnalysis
- Coursera plans layoffs after Udemy merger, estimates $8M-$11M in costs
Brookline Capital Markets Downgrades Tonix Pharma (TNXP) to Hold
July 27, 2018 10:04 AM EDTBrookline Capital Markets downgraded Tonix Pharma (NASDAQ: TNXP) from Buy to Hold.
For an analyst ratings summary and ratings history on Tonix Pharma click here. For more ratings news on Tonix Pharma click here.
Shares of Tonix Pharma closed at $3.95 yesterday.
... MoreUPDATE: B.Riley/FBR Downgrades Tonix Pharma (TNXP) to Neutral
July 27, 2018 10:04 AM EDT(Updated - July 30, 2018 9:04 AM EDT)
(updated to add analyst comment)
B.Riley/FBR downgraded Tonix Pharma (NASDAQ: TNXP) from Buy to Neutral with a price target of $1.25 (from $8.00).
Analyst David Buck comments "We downgrade our rating for Tonix Pharmaceuticals Holding... More
Tonix Pharma (TNXP) Halted on LUDP
July 27, 2018 9:59 AM EDTTonix Pharma (NASDAQ: TNXP) Halted on LUDP
... More